ORIC Pharmaceuticals has promising early data for ORIC-944 and ORIC-114, but remains in very early clinical stages. See why I ...

In Five Cancer Types, Prevention and Screening Have ... Nov. 20, 2024 — An enzyme called EZH2 has an unexpected role in driving aggressive tumor growth in treatment-resistant prostate cancers ...

T cell-based immunotherapies, including CAR-T cell therapies, have significantly advanced treatment options for lymphomas such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

Top of the list is Ipsen/Epizyme’s selective EZH2 inhibitor Tazverik (tazemetostat ... inhibitor sunvozertinib for non-small cell lung cancer (NSCLC) patients with EGFR Exon 20 insertions.

The agency gave accelerated approval to Tazverik in epithelioid sarcoma, a rare but serious connective tissue cancer. The company is also seeking approval for the drug, an EZH2 inhibitor ...

Novartis highlighted pelabresib, a BET inhibitor that recently generated mixed results in a phase 3 trial in myelofibrosis (MF), and dual EZH1/EZH2 inhibitor ... type of blood cancer that causes ...